Dr Sophia Rodriguez

Viking Global Investors LP (“Viking”) is a global investment firm founded in 1999. We employ a fundamentals-driven investment approach to managing over $57 billion of capital across public equity, private equity, and credit and structured capital strategies. Across our funds, our primary goal is to provide investors with best-in-class performance. We believe operational excellence is essential to our management of the capital with which we have been entrusted. We have more than 275 employees, including more than 50 investment professionals, across five offices: Stamford, New York, Hong Kong, London, and San Francisco. We seek to attract people who exhibit our Firm’s core values of intellectual honesty, integrity, continuous improvement, and accountability. Viking is registered as an investment adviser with the U.S. Securities and Exchange Commission. Please be aware that Viking’s name, brand, and reputation may be misused by unauthorized third parties. We do not provide investment advice or otherwise solicit capital via social media, including LinkedIn and Facebook, or encrypted chat platforms, including Telegram, WhatsApp, or Signal. If you receive a communication that appears suspicious, please report it to us at legalnotices@vikingglobal.com.

J&J Innovation Asia Pacific will partner with the Janssen R&D Immunology TA to host a hybrid onsite and online Science and Partnering forum convening global and regional leaders to engage in a dialogue on opportunities for accelerating solutions for patients with immune-mediated diseases through deals and incubation. The event will focus on engaging audiences of early-stage innovators in China, Japan and South Korea. The event will bring together internal and external experts to present and engage in panel discussions on current and future trends in immunology R&D and commercialization, as well as Janssen and Johnson & Johnson’s innovations approach to partnership with early-stage innovators in this therapeutic area, with a particular focus on the topics related to small molecule and platform solutions that address immune-mediated diseases impacting patients everywhere.

Exceptional entrepreneurs. Remarkable bonds. Extraordinary companies. Since 1996, Polaris has been guided by the fundamental beliefs that people come first and true partnerships make all the difference. Rooted in mutual respect and a shared passion for innovation, our relationships with outstanding visionaries principally in technology and healthcare have helped to change the world for the better.

Viking Global Investors LP (“Viking”) is a global investment firm founded in 1999. We employ a fundamentals-driven investment approach to managing over $57 billion of capital across public equity, private equity, and credit and structured capital strategies. Across our funds, our primary goal is to provide investors with best-in-class performance. We believe operational excellence is essential to our management of the capital with which we have been entrusted. We have more than 275 employees, including more than 50 investment professionals, across five offices: Stamford, New York, Hong Kong, London, and San Francisco. We seek to attract people who exhibit our Firm’s core values of intellectual honesty, integrity, continuous improvement, and accountability. Viking is registered as an investment adviser with the U.S. Securities and Exchange Commission. Please be aware that Viking’s name, brand, and reputation may be misused by unauthorized third parties. We do not provide investment advice or otherwise solicit capital via social media, including LinkedIn and Facebook, or encrypted chat platforms, including Telegram, WhatsApp, or Signal. If you receive a communication that appears suspicious, please report it to us at legalnotices@vikingglobal.com.